ANTHOS ANT 007 – Aster

About this trial

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE

Patient Profile

For patients with Cancer Associated Venous Thromboembolism

Where’s this trial being run?

Beaumont Hospital, Bon Secours Cork, Cork University Hospital, University Hospital Limerick, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	ANTHOS ANT 007 – Aster
Number:	24-11
Full Title:	A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE

Principal Investigator:	Dr Barry Kevane
Type:	Industry Sponsored
Sponsor:	Anthos Therapeutics, Inc.
Recruitment Started:	Global: Ireland:

Global Recruitment Target:	1655
Ireland Recruitment Target: